Trends in mortality from leukemia in subsequent age groups
Trends in mortality from leukemia in subsequent age groups
复制标题
DOI：
10.1038/sj.leu.2401915
复制
发表时间：
2000-11-01
期刊：
影响因子：
11.4
通讯作者：
La Vecchia, C
中科院分区：
文献类型：
--
作者：
Levi, F;Lucchini, F;La Vecchia, C
根据世界卫生组织的数据库，分析了欧洲联盟（欧盟）和世界其他发达地区1960-1997年期间各年龄组白血病年龄标准化死亡证明率的趋势。在欧盟，0-14岁的死亡率在1960-1964年达到高峰，1995-1997年死亡率下降了70%以上，男性为1.2/10万，女性为0.9/10万。在15-44岁年龄组中，男性下降了40%，女性下降了45%。在45-59岁年龄组中，下降幅度约为25%。在60-69岁的人群中，发病率在20世纪70年代末达到顶峰，随后女性的发病率仅下降了6%。在年龄大于或等于70岁的人群中，白血病死亡率一直上升到20世纪80年代末，此后趋于平稳。总体而言，在35年的日历期间，白血病死亡率的下降相当于每年避免约7000例死亡。在东欧，儿童和年轻人的下降开始较晚——在20世纪70年代末——儿童的下降不到40%，年轻人（15-44岁）的下降不到30%。在考虑的35年期间，白血病的总体年龄标准化死亡率没有明显变化。美国和日本的白血病死亡率从不同的数值开始，但与20世纪90年代末的欧盟相似，这表明治疗进步的影响在世界发达地区具有可比性。然而，在东欧，白血病死亡率的下降较晚，而且明显较小。
Trends in age-standardized death certification rates from leukemias in subsequent age groups were analyzed on the basis of the World Health Organization database over the period 1960-1997 in the European Union (EU) and other developed areas of the world. In the EU, the peak rate at age 0-14 was observed in 1960-1964, and the fall in mortality was over 70%, to reach 1.2/100 000 males and 0.9/100 000 females in 1995-1997. In the age group 15-44, the fall was about 40% for males and 45% for females. In the age group 45-59, the fall was around 25%. At age 60-69, the peak rate was observed in the late 1970s, and the subsequent fall was only 6% for females. At age greater than or equal to 70, leukemia mortality rose up to the late 1980s, and levelled off thereafter. Overall, the falls in leukemia mortality over the 35-year calendar period corresponded to the avoidance of about 7000 deaths per year. In eastern Europe, the falls in children and young adults started later - in the late 1970s - and were less than 40% for children and 30% for young adults (15-44 years). Overall age-standardized mortality from leukemia did not appreciably change over the 35-year period considered. Leukemia mortality rates in the USA and Japan started from different values, but were similar to those of the EU in the late 1990s, indicating that the impact of therapeutic advancements has been comparable in developed areas of the world. In eastern Europe, however, the declines in leukemia mortality were later and appreciably smaller.